Ipsen has appointed Michelle Werner as Executive Vice President (EVP), President of North America.
With a career spanning more than 25 years, she has gained experience in multiple roles, including as Director for Global Market Access for oncology and virology portfolios at Bristol Myers Squibb, Head of the Immuno-Oncology franchise and Oncology business unit in the US at Astra Zeneca and Global Franchise Head for Solid Tumors at Novartis Oncology.
Most recently, Werner was President and CEO of Alltrna, a US-based biotechnology company.
David Loew, CEO of Ipsen, said: “I am very pleased to welcome Michelle to Ipsen and to the Executive Leadership Team.
“She brings a wealth of experience in leading teams both in the US and around the world and has a deep understanding of the United States and all the great opportunities that this market offers for Ipsen at a moment when we are accelerating the growth of our portfolio in rare diseases, oncology and neurosciences. These are therapeutic areas where Michelle has excelled over her extensive career.”
Werner said: “Joining a company that brings together two therapeutic areas where I have deep passion and expertise, such as rare diseases and oncology, is one of those unique opportunities that comes at the right time in my journey.
“I look forward to working with the team to make a beneficial impact for the patients we serve.”